Form 4: Amicus Therapeutics Director Margaret McGlynn Executes Stock Options and Sells Shares Under 10b5-1 Plan

Director Margaret McGlynn exercised stock options and sold shares of Amicus Therapeutics, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 4, 2024, Margaret McGlynn, a director of Amicus Therapeutics, Inc., exercised options to acquire 7,500 shares of common stock at a price of $2.80 per share and sold 7,500 shares at $13.29 per share.
• On March 5, 2024, McGlynn again exercised options to acquire 7,500 shares of common stock at $2.80 per share and sold 7,500 shares at $13.40 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 10, 2023.
• Following these transactions, McGlynn directly owns 59,289 shares of Amicus Therapeutics common stock.
• McGlynn also owns 0 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. There is no indication of positive or negative sentiment towards the company's prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan is a common practice to allow insiders to sell shares without raising concerns about trading on non-public information.

Comparison to Industry Standards

• Comparing McGlynn's transactions to those of other directors in similar biotech companies would require analyzing their Form 4 filings.
• The use of a 10b5-1 trading plan is a standard practice among corporate executives and directors to manage their stock holdings while avoiding insider trading accusations.
• The size and frequency of these transactions are not unusual for directors in publicly traded companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan suggests no material impact is expected.

Key Dates